Results 21 to 30 of about 308,973 (266)
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj +1 more source
Aims: Epidermal growth factor receptor mutation analysis in non-small cell lung cancer is important for selecting patients who will receive treatment with tyrosine kinase inhibitors.
Gaye Güler Tezel +3 more
doaj +1 more source
Epidermal growth factor receptor in glioblastoma
Mutations in the epidermal growth factor receptor (EGFR) are commonly occurring in glioblastoma. Enhanced activation of EGFR can occur through a variety of different mechanisms, both ligand-dependent and ligand-independent. Numerous evidence has suggested that EGFR is overexpressed in most of primary glioblastomas and some of the secondary ...
Xu, Hongsheng +8 more
openaire +3 more sources
Introduction: EGFR targeted therapies, have been proved beneficial for patients with HCC, nevertheless additional research on EGFR immunoexpresion and EGFR mutations is still needed, especially in population in which it has not been done yet.
Nikolova Dafina +5 more
doaj +1 more source
Gallbladder cancer has poor prognosis and limited therapeutic options. Arctigenin, a representative dibenzylbutyrolactone lignan, occurs in a variety of plants.
Mingdi Zhang +11 more
doaj +1 more source
Targeted therapies such as kinase inhibitors and monoclonal antibodies have dramatically altered cancer care in recent decades. Although these targeted therapies have improved patient outcomes in several cancer types, resistance ultimately develops to ...
Leanne G. Ahronian, Ryan B. Corcoran
doaj +1 more source
Background Human epidermal growth factor receptor2+ subtype breast cancer has a high degree of malignancy and a poor prognosis. The aim of this study is to develop a prediction model for the human epidermal growth factor receptor2+ subtype (non-luminal ...
Jin Zhou +9 more
doaj +1 more source
Epidermal Growth Factor Receptor Pathway [PDF]
The epidermal growth factor receptor (EGFR) pathway has provided a new therapeutic target in non-small cell lung cancer (NSCLC). Two EGFR tyrosine kinase inhibitors (TKIs) are being used globally as systemic treatment in advanced NSCLC. In addition, clinical observations with EGFR TKIS led to the discovery of EGFR activating mutations, which has ...
openaire +2 more sources
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics.
Carlos E. Bacchi +5 more
doaj +1 more source
This case report describes a unique pattern of human epidermal growth factor receptor 2 expression in a patient with uterine carcinosarcoma. The endometrial tumor showed biphasic morphology composed of serous carcinoma and a heterologous high-grade ...
Joseph Gillam +5 more
doaj +1 more source

